Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042562 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00042562: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00042562 is a Phase 3 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042562, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. The safety associated with switching from a medication you may be taking for depression to taking duloxetine. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate duloxetine for other possible uses or for other medical or scientific purposes other than those currently proposed.
Interventions
- DRUG duloxetine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-12 |
| Est. Completion | 2003-12 |
| Phase | Phase 3 |
What the finished NCT00042562 record still lists
NCT00042562 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which duloxetine is the first listed.
NCT00042562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00042562 about?
NCT00042562 is a clinical study titled "Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression". The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. The safety associated with switching from a medication you may be taking for depression to taking duloxetine. I...
What is the current status of trial NCT00042562?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-12. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00042562?
The interventions under investigation include: duloxetine (DRUG).
Who is sponsoring clinical trial NCT00042562?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia